

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTC

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)


Sheet 1 of 4

<i>Complete If Known</i>	
Application Number	10/748,096
Filing Date	December 30, 2003
First Named Inventor	Doddabele L. Madhavi
Art Unit	1623
Examiner Name	Matthew L. Fedowitz
Attorney Docket Number	BIO 2-013

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ² Number ⁴ "Kind Code ⁵ (if known)			
	EP1174109		01-23-2003	Nielsen, et al.	
	JP56109590		08-31-1981	Yonezawa, et al.	

Examiner Signature		Date Considered	9/30/05
--------------------	---	-----------------	---------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

4

Complete If Known

Application Number	10/748,096
Filing Date	December 30, 2003
First Named Inventor	Doddabele L. Madhavi
Art Unit	1623
Examiner Name	Matthew L. Fedowitz
Attorney Docket Number	BIO 2-013

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
		Application Number	10/748,096		
		Filing Date	December 30, 2003		
		First Named Inventor	Doddabele L. Madhavi		
		Art Unit	1623		
		Examiner Name	Matthew L. Fedowitz		
Sheet	3	of	4	Attorney Docket Number	BIO 2-013

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	11	"Transepithelial transport of putrescine across monolayers of the human intestinal epithelial cell line, Caco2", World J. Gastroenterol., 7: 193-197, 2001.		
	12	"Improvement of dissolution and absorption characteristics of ubidecarenone by dimethyl- β -cyclodextrin complexation", Acta Pharm. Nord., 1: 99-104, 1989.		
	13	"The effect of parenterally administered cyclodextrins on cholesterol levels in the rat", Pharm. Res., 8: 9-16, 1991		
	14	"Studies on the inclusion compound between β -cyclodextrin and cholesterol", In D. Duchene (Ed), 5th International Symposium on Cyclodextrins, 1990, pp 299-302, Editions de Sante, Paris		
MF	15	"Cyclodextrins as carriers of cholesterol and fatty acids in cultivation of mycoplasmas", Appl. Envr. Microbiol., 59: 547-551, 1993).		
MF	16	"Comparison of impact of the different hydrophilic carriers on the properties of piperazine-containing drug", Eur. J. Pharm. Biopharm., 51: 221-225, 2001.		
	17	"Comparative study on inclusion complexation of maltosyl-beta-cyclodextrin, heptakis(2,6-di-O-methyl)-beta-cyclodextrin and beta-cyclodextrin with fucosterol in aqueous and solid state", J. Pharm. Pharmacol., 45: 1028-32, 1993		
MF	18	"Effect of inclusion complexation with cyclodextrins on photostability of nifedipine in solid state", Int. J. Pharm., 243: 107-17, 2002		
MF	19	"Enhancement of dissolution and oral bioavailability of gliquidone with hydroxypropyl-beta-cyclodextrin", Pharmacia, 2003: 58 (11): 807-10		
MF	20	Physicochemical characterization and in vitro dissolution behavior of nicardipine hydrochloride inclusion compounds". Eur J Pharm Sci. 2002 Feb; 15(1): 79-88		

Examiner Signature		Date Considered	9/30/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

4


of

4

<i>Complete if Known</i>	
Application Number	10/748,096
Filing Date	December 30, 2003
First Named Inventor	Doddabele L. Madhavi
Art Unit	1623
Examiner Name	Matthew L. Fedowitz
Attorney Docket Number	Bio 2-013

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>MLF</i>	21	Effect of the hydrophobic nature of triacetyl-beta-cyclodextrin on the complexation with nicardipine hydrochloride: physicochemical and dissolution properties of the kneaded and spray-dried complex*, Chem Pharm Bull (Tokyo). 2002 Dec; 50 (12): 1597-602	
<i>MLF</i>	22	"Preparation and characterization of albendazole beta-cyclodextrin complexes", Drug Dev Ind Pharm. 1999 Dec; 25(12) :12418	
<i>MLF</i>	23	"Influence of the preparation method on the physicochemical properties of ketoprofen-cyclodextrin binary systems", Int J Pharm. 1999 Mar 1; 179(1): 117-28	
<i>MLF</i>	24	"Influence of the preparation method on the physicochemical properties of binary systems of econazole with cyclodextrins", Int J Pharm. 1999 Dec 20; 193(1): 85-95	
<i>MLF</i>	25	"Review-Cyclodextrins in topical drug formulations: Theory and Practice", Int. J. Pharm., 225: 15-30, 2001	

Examiner Signature		Date Considered	<i>9/30/03</i>
--------------------	---	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.